Clinical Trial Update: A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of ASTX660 in relapsed or refractory T-cell lymphomas has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• ASTX660

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-02-25